Shape therapeutics ipo
WebbBEAM-201. Edit type: Multiplex editing. Delivery modality: Electroporation Ex vivo. Approach: Gene silencing. BEAM-201 is a multiplex base edited anti-CD7 CAR-T cell investigational therapy for relapsed and refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, a severe disease affecting children and adults. Webb5 nov. 2024 · Shape Therapeutics, Inc. raises $35.5M Series A financing, led by NEA and announces the formation of a world-class Scientific Advisory Board, to advance a first-in-class RNA editing gene therapy platform focused on curing genetic diseases. November 5, 2024 - Posted in All News, Press Releases .
Shape therapeutics ipo
Did you know?
Webb25 aug. 2024 · On August 24th, Swiss pharma giant Roche announced that it will collaborate with Shape Therapeutics, a Seattle-based biotech specializing in RNA editing … Webb11 feb. 2024 · CAMBRIDGE, Mass.– (BUSINESS WIRE)– Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its...
Webb22 juni 2024 · The $1.6 billion valuation attached to its SPAC deal puts Pear at the head of its rivals in terms of funding raised. In May, fellow digital therapeutics company Akili raised new financing at a... Webbför 16 timmar sedan · 10 stocks we like better than Intellia Therapeutics When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a …
WebbDetails: During the course of the partnership, ShapeTX will conduct preclinical research to identify and deliver development candidates discovered by its AI-powered platforms RNAfix™ and, potentially, AAVid™. Lead Product (s): AAV-based Gene Therapy. Therapeutic Area: Neurology Product Name: Undisclosed. Highest Development Status ... Webb8 dec. 2024 · Shape Therapeutics, Inc., a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment …
Webb23 juni 2024 · DTx company Pear shapes public listing with $1.6bn SPAC merger News Digital health company Pear Therapeutics has foregone the traditional initial public …
WebbAnalyst. Nielsen. Feb 2014 - Jan 20151 year. Waltham, MA. Nielsen is a global market research company with leading market positions in marketing and consumer … can makeup expireWebb5 nov. 2024 · SEATTLE-- ( BUSINESS WIRE )-- Shape Therapeutics, Inc. (ShapeTx), a development-stage biotechnology company leading the field of RNA-editing gene therapy, announces $35.5M in Series A financing, led by New Enterprise Associates (NEA), with additional participation from CureDuchenne Ventures. can makeup cause cystic acneWebb10 apr. 2024 · (Bloomberg) -- Senator Elizabeth Warren of Massachusetts and Representative Alexandria Ocasio-Cortez of New York sent letters Sunday to 14 of the largest depositors with Silicon Valley Bank that raised concerns over the failed bank’s relationship with some of the venture capitalists and tech founders who made up much … fixed asset physical count sheetWebb16 juli 2024 · Shape Therapeutics, a Seattle preclinical stage biotech company developing RNA editing and gene therapy technologies, has raised $112 million. The company’s RNA … fixed asset process in sapWebbHow to Get a Promotion. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. This is the Shape Therapeutics company profile. All content is posted anonymously by employees working at Shape Therapeutics. Argentina. Australia. België (Nederlands) Belgique ... fixed asset proceduresWebbShapeTX Stock. shapetx.com Healthcare Founded: 2024 Funding to Date: $138.25MM. Shape Therapeutics is a biotechnology company focused on developing breakthrough … fixed asset project d365Webb12 maj 2024 · Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of 2024’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. canmaking equipment